Kornimate/medical-research-clean huggingface dataset:
inflammatory response to anti inflammatory therapy in children with sleep disordered breathing

Conditions: Sleep Disordered Breathing

Summary: this study will assess in a double blind placebo controlled fashion the effects of a 12 week course of oral montelukast/placebo on polysomnographic and radiological findings and will characterize the systemic (serum,urine) and local (upper airway collected biological samples) inflammatory response in children (2-10 years of age) with sleep disordered breathing, fittingthe inclusion and exclusion criteria.


Eligibility criteria:
inclusion criteria:2-10 years old 1\<ahi\<8 measured in an overnight psg - exclusion criteria: asthma previous use or allergy to montelukast use of antibiotics in the previous 3 weeks use of corticosteroids in the previous 3 months craniofacial dysmorphism genetic or metabolic defined illnesses adenotonsillectomy or adenoidectomy in the past -
effect of anti-hiv therapy (haart) on hiv levels in the lungs and on lung cell inflammation in hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to see: (1) how the amount of hiv in the lungs compares to that in the blood; (2) if haart reduces the amount of hiv in the lungs; and (3) if haart reduces lung inflammation in hiv-infected patients. lung-cell inflammation in hiv-infected patients is probably caused by hiv infection of these cells. the amount of inflammation may correspond to the amount of hiv (viral load) in the lungs (i.e., mild inflammation indicates a low amount of hiv; severe inflammation indicates a high amount of hiv). haart is used to decrease the amount of hiv in the body. if haart is able to decrease viral load in the lungs, it should also be able to decrease lung-cell inflammation in these patients.

lymphocytic alveolitis in hiv-infected patients probably represents a local immune response to hiv-infected cells in the lung. the intensity of lymphocytic alveolitis may therefore reflect the viral load in the lung. if so, treatment that reduces viral load in the lung (e.g., haart) should also decrease the number of cytotoxic t lymphocytes (ctls) in the alveolar space and should return pulmonary immune responses toward normal. patients are stratified by cd4 count: less than 200 cells/mm3 or 200 - 500 cells/mm3. bal is performed and blood samples are collected prior to initiation of haart and after 1 and 6 months of haart. if a patient has detectable hiv in the lung after 6 months of haart, the patient is asked to submit to an optional fourth bal after 12 months of haart. bal fluid and cells are analyzed for hiv viral load, percent lymphocytes, and lymphocyte subsets. responses in the lung are compared to simultaneous changes in these variables found in the peripheral blood. each patient serves as his/her own control.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are hiv-positive. * are at least 18 years old. * have a cd4 count less than or equal to 500 cells/mm3 and an hiv rna level greater than or equal to 5000 copies/ml. * are about to start a regimen of at least 3 anti-hiv drugs (haart). exclusion criteria patients will not be eligible for this study if they: * have ever received protease inhibitors (pis) or nonnucleoside reverse transcriptase inhibitors (nnrtis). * have had signs or symptoms of lung disease in the past 30 days (pneumonia, bronchitis, emphysema, asthma, severe cough, or severe shortness of breath). * have received certain medications, including hiv vaccines. * have received chemotherapy within 30 days prior to study entry, or have cancer that will require chemotherapy. * are pregnant and will be beyond the first 3 months of pregnancy by week 24 (month 6) of the study.

Keywords: lung hiv-1 viremia anti-hiv agents viral load bronchoalveolar lavage fluid
covid-19 mortality prediction model

Conditions: COVID-19; Pneumonia; Mechanical Ventilation

Summary: the objective of this study is to develop and evaluate an algorithm which accurately predicts mortality in covid-19, pneumonia and mechanically ventilated icu patients.

retrospective study of 53,001 total icu patients, including 9,166 patients with pneumonia and 25,895 mechanically ventilated patients, performed on the mimic dataset. the nph patient dataset includes 114 patients positive for sars-cov-2 by pcr test.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or older * record of icu stay exclusion criteria: * patients aged less than 18 years * patients for which there were no records of raw data or no discharge or death dates.

Keywords: machine learning covid-19 mortality prediction pneumonia mechanical ventilation
tele-epic (telemedicine for epilepsy care)

Conditions: Epilepsy; Epileptic Encephalopathy; Refractory Epilepsy

Summary: epilepsy is a chronic condition that requires consistent follow-up aimed at seizure control, surveillance of comorbidities, monitoring of antiepileptic drugs (aed) levels and side effects. patients may encounter difficulties to be assessed adequately and the disease burden is increased by the need for travelling across the country for medical consultations. driving restrictions are a further limit to access specialized centers able to provide an integrated approach focused on patient needs. telemedicine (tm) offers an invaluable support to patient follow-up, joining the sparse distribution of patients in the country with the prompt availability of a team of experts. the project assesses, through a randomized controlled trial, the non-inferiority of tm in monitoring seizure control compared to usual (face-to-face) care. this approach, coupled with a new self home-sampling method for the measurement of aed levels, will reduce health care costs and simplify patients management.


Eligibility criteria:
inclusion criteria: * adult (age\>18 yrs) and pediatric (age\<18yrs) outpatients with established diagnosis of epilepsy.

Keywords: telemedicine epilepsy antiepileptic drugs monitoring
efficacy of acetaminophen-ibuprofen combination on the postoperative pain after thyroidectomy

Conditions: Thyroid Disease

Summary: acetaminophen and ibuprofen has been safely used for a long time and reduces postoperative pain and opioid dosages. investigators are planning to compare the efficacy of 1) acetaminophen only and 2) acetaminophen and ibuprofen combination at postoperative pain after thyroidectomy.

acetaminophen and ibuprofen has been safely used for a long time and reduces postoperative pain and opioid dosages. investigators are planning to compare the efficacy of 1) acetaminophen 1g only and 2) the combination of acetaminophen 1g and ibuprofen 300mg at postoperative pain after thyroidectomy. some recovery valuables such as the postoperative pain and opioid requirements will be assessed

Eligibility criteria:
inclusion criteria: * the patients undergoing scheduled thyroidectomy * american society of anesthesiologists status 1 or 2 exclusion criteria: * refusal to be enrolled in the study * emergency surgery * hepatic or renal disease * on chronic pain medications * psychiatric disorders * pregnancy, lactation * allergy or contraindication to the study drug
assessing outcome after h-graft shunt placement

Conditions: Portal Hypertension

Summary: the objective of this study is to evaluate the pre-operative symptoms and medical history of patients with portal hypertension who have undergone placement of h-graft portacaval shunts and correlate this with patient outcomes.

research data will be collected by accessing the tampa general hospital medical record charts as well as the harbourside medical charts, and extracting the necessary research data. the charts will be reviewed for the relevant medical information in order to assess outcomes in patients having h-graft shunts placed for the treatment of portal hypertension.

Eligibility criteria:
inclusion criteria: * patients who have had h-graft shunts placed for the treatment of portal hypertension. exclusion criteria: * patients under the age of 18 will not be included in this study.

Keywords: portal hypertension, h-graft shunt
characteristics and consequences of coronary angiograms performed in intensive care patients

Conditions: Acute Coronary Syndrome

Summary: coronary angiography is a key examination in the management of many patients hospitalized in intensive care units. the most frequent indication remains the performance of a gesture of unblocking of part of the coronary network in the context of an acute coronary syndrome (acs) complicated by cardiogenic shock (cs) and/or cardiac arrest. cardio-respiratory (acr). however, there are other indications in intensive care, in particular for diagnostic purposes. given the lack of harmlessness of this procedure in itself and the consequences of intra-hospital transport outside intensive care units for patients who are sometimes very unstable, the risk-benefit balance before performing a coronary angiography requires always be properly assessed by the resuscitating physician.


Eligibility criteria:
inclusion criteria: * adult patient (≥18 years old) * patients hospitalized in intensive medicine - resuscitation between january 1, 2015 and january 1, 2020 in whom a coronary angiography was performed. * patient not objecting to the reuse of their data for scientific research purposes. exclusion criteria: • patient who has expressed his opposition to the reuse of his data for scientific research purposes.

Keywords: acute coronary syndrome coronary angiography cardiogenic shock cardio-respiratory arrest
twelve transcatheter mitral valve replacement (tmvr) pilot study

Conditions: Mitral Valve Insufficiency

Summary: study to evaluate the safety and performance of the twelve tmvr system

the study is a prospective, multi-center, non-randomized trial to evaluate the safety and performance of the twelve tmvr system in very high risk patients with severe, symptomatic mitral regurgitation.

Eligibility criteria:
key inclusion criteria: * severe mitral regurgitation (mr grade 3-4+) * symptomatic mitral regurgitation (nyha class ii-iv) * trans-apical access deemed feasible by the treating physician * native mitral valve geometry and size compatible with the twelve tmvr key exclusion criteria: * left ventricular ejection fraction (lvef) \< 20 * evidence of intracardiac mass, thrombus, or vegetation * prior valve surgery or need for other valve surgery * prior stroke within 4 weeks * need for coronary revascularization * history of, or active, endocarditis * renal insufficiency (creatinine \> 2.5 mg/dl)
clinical observation of pulsed dye laser and intense pulsed light in treating facial telangiectasia

Conditions: Telangiectasia

Summary: 1. facial telangiectasia is one of the common skin vascular lesions characterized by dilated cutaneous vasculatures in the skin surface or mucous membranes. lesions are generally sensitive to exposure of cold, heat and sun. those distinct small dilated blood vessels are cosmetically disfiguring for patients which require an effective solution. the traditional management options for facial telangiectasia include cryotherapy, co2 laser, topical agent, oral estrogens, electrosurgery, and radioactive treatment. however, inadequate outcomes and severe adversaries are the major concerns to patients and physicians. 2. pulsed dye laser (pdl) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis. the intense pulsed light source is an alternative or supplement to the already existing laser devices that are part of the laser surgeon's repertoire. the broad wavelength spectrum and variable pulse duration allow greater penetration depths to be reached without damaging surrounding tissue and thus enhance the versatility of this system. 3. this study aims to compare the clearance efficacy of facial telangiectasia using pdl (595nm) with ipl configured by various wavelength bands, including m22 vascular filter (530-650nm and 900-1200nm), m22 560 (560-1200nm), m22 590 (590-1200nm) .

detailed description has not been entered.

Eligibility criteria:
inclusion criteria: * subjects must be clinically diagnosed with facial telangiectasia * no other external treatment was performed before the injury was treated exclusion criteria: * subjects with a recent history of exposure to sunlight * subjects allergic to topical anesthesia * subjects with scar constitution * subjects with skin malignant tumors or precancerous lesions * subjects with diabetes, heart disease, epilepsy, connective tissue disease, etc * subjects who pregnant or breast feeding * subjects with recent skin infections (such as viruses, bacteria, etc.) * other methods are being used to treat subjects with similar diseases * subject who have taken isotretinoin a in the past year * subject with facial dermatitis

Keywords: facial telangiectasia pulsed dye laser (pdl) intense pulsed light
the efficacy of azvudine and paxlovid in high-risk patients with covid-19: a prospective randomized controlled trial

Conditions: SARS-CoV-2 Infection

Summary: this is a randomized controlled clinical study on the clinical efficacy of azvudine and paxlovid antivirus therapy in covid-19 patients with high-risk. the objective is to examine the effect of high-risk on the time for covid-19 patients to achieve 2 continuously negative sars-cov-2 nucleic acid test result, and the rt-pcr negative conversion rates in day 7. patients who meet inclusion criteria will be randomized into the azvudine group (treatment group) and paxlovid group (control group).

after enrollment, patients will be randomized into treatment or control groups. patients received azvudine orally, for 7 consecutive days (7 doses in total) or paxlovid orally for 5 consecutive days (10 doses in total). the test for rt-pcr test through either nasopharyngeal or oropharyngeal swabs were conducted on a daily basis from day 3 of their hospitalization until conversion was observed. the primary outcome was the proportion of patients acheive 2 continuously rt-pcr negative for sars-cov-2 at 7 days following treatment initiation, including both orf gene ct value≥35 and n gene ct value≥35. secondary outcomes included 1) the proportion of patients rt-pcr negative for sars-cov-2 at 14 days; 2) the time to conversion from a positive rt-pcr test to 2 continuously negative test; 3) 14-day treatment failure rate (need mechanical ventilation or high-flow oxygen therapy or death).

Eligibility criteria:
inclusion criteria: * patients aged 18-85 years (inclusive). * meet the diagnostic criteria for covid-19. * at least one high risk factor for progression to severe covid-19 * no more than 5 days from the onset of clinical symptoms * sign informed consent form. exclusion criteria: * severe or critically patients with covid-19 * have received neutralizing antibodies or convalescent plasma therapy due to covid-19 * child-pugh grade c or acute liver failure * chronic renal failure (egfr\<30 ml/min) * grade iii or iv cardiac function, or known left ventricular ejection fraction \< 30% * known or suspected history of active or extrapulmonary tuberculosis * patients who are allergic to the active ingredient of the drug * pregnant and lactating women

Keywords: sars-cov-2 antivirus covid-19
a study of adagrasib plus pembrolizumab plus chemotherapy vs. placebo plus pembrolizumab plus chemotherapy in participants with previously untreated non-squamous non-small cell lung cancer with kras g12c mutation (krystal-4)

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic nsclc with kras g12c mutation


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of non-squamous nsclc with evidence of kras g12c mutation via tumor tissue and/or circulating tumor deoxyribonucleic acid (ctdna). * locally advanced or metastatic disease. * measurable disease via computed tomography (ct) or magnetic resonance imaging (mri) per recist v1.1 criteria of at least 1 lesion. * no prior systemic anti-cancer therapy given for advanced or metastatic disease. * not a candidate for definitive therapy (eg, chemoradiation or complete surgical resection). * participants with brain metastases are eligible for enrollment, including those with untreated brain metastases. brain metastases must be asymptomatic and not in need of immediate local therapy. any untreated brain metastases must be ≤ 20 mm in diameter. * any pd-l1 expression (0 to 100%) as determined by ventana pd-l1 (sp263) assay, agilent pd-l1 ihc 22c3 pharmdx, or agilent pd-l1 ihc 28-8 pharmdx. exclusion criteria: * participants with an active, known, prior documented, or suspected autoimmune or inflammatory disease. * uncontrolled or significant cardiovascular conditions within 6 months prior to enrollment. * inadequate bone marrow or liver function or electrocardiogram (ecg) abnormalities. * ongoing treatment with concomitant medication known to cause prolonged qtc interval and that cannot be switched to alternative treatment prior to study entry. * treatment targeting kras g12c mutation (eg, sotorasib, adagrasib) in any setting. * other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration. * other protocol-defined inclusion/exclusion criteria apply.

Keywords: immunotherapy kras kras g12c targeted therapy
research on nicorandil treatment of patients diagnosed as chd (coronary heart disease) with stable angina

Conditions: Stable Angina; Coronary Disease

Summary: this study of 402 cases of stable angina subjects who were diagnosed as coronary heart disease (chd) is a randomized, blank controlled, multi-center clinical study. subjects who are taking standard treatment with stable symptoms will receive a 24-hour ambulatory electrocardiogram (ecg) (holter) examination. they will be randomly divided into two groups. the nicorandil group will receive nicorandil 5 milligram (mg) (3 times a day = tid) on top of the standard treatment for 12 weeks, while the control group will stay on standard treatment. nitrates and beta blockers need to be maintained on a stable dose. other drugs that do not affect the primary endpoint may be adjusted per investigators decision.


Eligibility criteria:
inclusion criteria: * subject must be diagnosed as stable chd, and must have at least one of these histories: 1. a history of coronary revascularization percutaneous coronary intervention (pci) or coronary artery bypass surgery at least 3 months ago 2. myocardial infarction 3. more than 50 percent (%) stenosis detected by angiography 4. exercise tolerance testing (ett) or computed tomography angiography (cta) showed more than 50% stenosis with typical angina symptoms * subjects must have at least 2 times of typical symptoms of myocardial ischemia occurred within a week other protocol defined inclusion criteria could apply exclusion criteria: * coronary syndrome or considering acute coronary syndrome (acs) * left main coronary artery disease without revascularization * aortic stenosis * obstructive hypertrophic cardiomyopathy * subjects with hypertension systolic blood pressure (sbp) greater than (\>) 170 millimeters of mercury (mmhg) or diastolic blood pressure (dbp) \>100 mmhg) or hypotension (sbp less than \[\<\] 90 mmhg or dbp\<60 mmhg) * diagnosis as postural hypotension before * congestive heart failure (new york heart association \[nyha\] class iii - iv * ejection fraction (ef)\<40% by echocardiography * arrhythmias requiring active treatment * gastro-intestinal ulcer * concomitant medication such as sulphonyl urea, pde-5 inhibitor such as sildenafil, trimetazidine for treatment of angina pectoris other protocol defined exclusion criteria could apply

Keywords: nicorandil stable angina
evaluation of low-level light therapy on meibomian glands study

Conditions: Meibomian Gland Dysfunction; Dry Eye

Summary: the goal of this clinical trial is to examine the effect of low-level light therapy (lllt) on meibomian gland dysfunction and dry eye disease. the main questions it aims to answer are: 1. does low-level light therapy reduce levels of pro-inflammatory proteins in meibum 2. does low-level light therapy increase the ratio of non-polar lipids to polar lipids in meibum participants will receive 3 15-minute sessions of low-level light therapy. meibum will be collected before the first treatment and after the final treatment.

low-level light therapy (lllt) is a treatment for meibomian gland dysfunction. the proposed mechanism of action is photobiomodulation of cells leading to improved adenosine triphosphate synthesis, reduction of reactive oxygen species in oxidatively-stressed cells, and the activation of transcription factors involved in cellular proliferation, migration and survival. understanding of how low-level light therapy based therapy alters meibomian gland function is poor. this study will examine the effect of low-level light therapy on individuals with meibomian gland dysfunction. eligible subjects will receive 15 minutes of low-level light therapy per week over a 3 week period. meibum collected prior to treatment will be compared to meibum collected after 3 treatment sessions for alteration in protein and lipid composition.

Eligibility criteria:
inclusion criteria: * age 18 years or older at enrollment * individuals with mild to moderate meibomian gland dysfunction based on clinical signs, e.g., meibum quality score of 1-3, meibography score of 1, 2, or 3 on the pult meiboscale, non-invasive 1st tear break up time of 10 seconds or less, or an ocular surface disease index (osdi) score of 13 to 32 points exclusion criteria: * history of systemic disease associated with aqueous-deficient dry eye disease (e.g., sjogren's syndrome) * history of corneal surgery, refractive surgery, eyelid surgery or ocular trauma within 6 months * history of lipiflow, ilux, meiboflow, intense pulsed light (ipl) or low level light therapy (lllt) within the last 12 months * use of photosensitizing medications * pregnant and/or lactating females * pigmented lesions, tattoos, or skin cancer in the periocular region

Keywords: meibomian glands meibomian gland dysfunction tears